Australia’s Sigma Blocked From Marketing Effexor Generic
This article was originally published in PharmAsia News
Executive Summary
Sigma Pharmaceuticals of Australia lost a case in federal court in its attempt to market a generic version of U.S.-based Wyeth's antidepressant Effexor (venlafaxine). The court issued an injunction against Sigma marketing the drug until the validity of Wyeth's patent for Effexor is determined later this year in another court. Sigma already had begun importing its generic copy, Evelexa, and had been contacting possible customers about a drug it expected to deliver as early as June 1. (Click here for more
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.